CN103183604A - Preparation method of vedaprofen - Google Patents

Preparation method of vedaprofen Download PDF

Info

Publication number
CN103183604A
CN103183604A CN2011104485722A CN201110448572A CN103183604A CN 103183604 A CN103183604 A CN 103183604A CN 2011104485722 A CN2011104485722 A CN 2011104485722A CN 201110448572 A CN201110448572 A CN 201110448572A CN 103183604 A CN103183604 A CN 103183604A
Authority
CN
China
Prior art keywords
reaction
compound
acid
catalyst
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011104485722A
Other languages
Chinese (zh)
Other versions
CN103183604B (en
Inventor
王元
徐颖超
梅会群
何训贵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
2Y-CHEM LTD
Original Assignee
2Y-CHEM LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2Y-CHEM LTD filed Critical 2Y-CHEM LTD
Priority to CN201110448572.2A priority Critical patent/CN103183604B/en
Publication of CN103183604A publication Critical patent/CN103183604A/en
Application granted granted Critical
Publication of CN103183604B publication Critical patent/CN103183604B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及维达洛芬的制备方法。本发明提供的方法只有四步反应,所需原料都是常规原料,而且该方法易于操作,所有步骤均可以采用”一锅法”进行,便于工业化生产。

Figure DEST_PATH_DDA0000154227920000011
The invention relates to a preparation method of vidaprofen. The method provided by the invention has only four steps of reaction, the required raw materials are all conventional raw materials, and the method is easy to operate, and all steps can be carried out by "one-pot method", which is convenient for industrial production.
Figure DEST_PATH_DDA0000154227920000011

Description

维达洛芬的制备方法The preparation method of vidaprofen

技术领域 technical field

本发明涉及一种维达洛芬的制备方法。The invention relates to a preparation method of vidaprofen.

背景技术 Background technique

如下结构式1所示的维达洛芬(vedaprofen)是化合物2-(4-环己基萘基)丙酸的通用药品名称。Vidaprofen (vedaprofen) shown in the following structural formula 1 is the generic drug name of the compound 2-(4-cyclohexylnaphthyl)propionic acid.

Figure BDA0000126142220000011
Figure BDA0000126142220000011

维达洛芬属于2-芳基丙酸类化合物,是一种用于解热、镇痛的非甾类消炎药,主要应用于痛风、内分泌及代谢类疾病。该化合物有一个手性中心,因此有S(+)和R(-)一对对映异构体。现代药理学研究证明,维达洛芬的S(+)和R(-)构型在对前列腺素(PGF)的抑制作用上是完全相同的,因此这两种构型都是优性异构体。维达洛芬的消旋体混合物已经被开发成为马类和犬科类兽药,目前在欧美已经被许可用于狗和马的治疗。因此,合成维达洛芬无需不对称合成或手性拆分,得到消旋体即可。Vidaprofen belongs to 2-arylpropionic acid compounds and is a non-steroidal anti-inflammatory drug used for antipyretic and analgesic. It is mainly used in gout, endocrine and metabolic diseases. The compound has a chiral center and therefore has a pair of enantiomers, S(+) and R(-). Modern pharmacological studies have proved that the S(+) and R(-) configurations of vidaprofen are completely the same in the inhibitory effect on prostaglandins (PGF ), so these two configurations are superior and different. Construct. The racemic mixture of vidaprofen has been developed into equine and canine veterinary drugs, and has been approved for the treatment of dogs and horses in Europe and America. Therefore, there is no need for asymmetric synthesis or chiral resolution to synthesize vidaprofen, only the racemate can be obtained.

通过文献检索,其文献或专利报道的主要合成路线和方法有如下两种:Through literature search, the main synthetic routes and methods reported in the literature or patents are as follows:

例如,美国专利US4218473公开了一种维达洛芬的制备方法,反应式如下:For example, U.S. Patent US4218473 discloses a kind of preparation method of vidaprofen, and reaction formula is as follows:

Figure BDA0000126142220000021
Figure BDA0000126142220000021

以1-环己基萘(可以参照文献Journal of the American Chemical Society,2004,126(12),3686-3687制备而得)为起始原料,首先与甲醛、浓盐酸进行氯甲基化反应得到1-氯甲基-4-环己基萘;得到的氯甲基化中间体用氰化钠氰基化,再水解氰基得到中间体4-环己基-1-萘乙酸;得到的酸中间体用甲醇酯化成相应甲酯,再用碘甲烷在α位甲基化,得到2-(4-环己基萘基)丙酸甲酯;该甲酯通过碱性条件水解并用盐酸酸化得到维达洛芬。Taking 1-cyclohexylnaphthalene (which can be prepared with reference to the document Journal of the American Chemical Society, 2004, 126 (12), 3686-3687) as a starting material, firstly carry out chloromethylation reaction with formaldehyde and concentrated hydrochloric acid to obtain 1 -Chloromethyl-4-cyclohexylnaphthalene; The obtained chloromethylated intermediate is cyanated with sodium cyanide, and then the cyano group is hydrolyzed to obtain the intermediate 4-cyclohexyl-1-naphthalene acetic acid; The acid intermediate obtained is used Methanol is esterified to the corresponding methyl ester, and methylated at the α position with methyl iodide to obtain methyl 2-(4-cyclohexylnaphthyl) propionate; the methyl ester is hydrolyzed under alkaline conditions and acidified with hydrochloric acid to obtain Vidaprofen .

该路线需用氰化钠和碘甲烷等剧毒管制品,大规模生产时极大威胁操作人员的人身健康和安全。另外,这种方法路线较长,步骤较多,含6步反应,生产成本较高。This route requires the use of highly toxic controlled products such as sodium cyanide and methyl iodide, which greatly threaten the personal health and safety of operators in large-scale production. In addition, this method has a long route and many steps, including 6-step reactions, and the production cost is relatively high.

根据文献【Journal of medicinal chemistry,2007,50(12),2787-2798和Tetrahedron,1995,51(46),12583-12590】,也可以得到一种维达洛芬的制备方法,反应式如下:According to the literature [Journal of medicinal chemistry, 2007, 50 (12), 2787-2798 and Tetrahedron, 1995, 51 (46), 12583-12590], a preparation method of vidaprofen can also be obtained, and the reaction formula is as follows:

Figure BDA0000126142220000022
Figure BDA0000126142220000022

以1-环己基萘为起始原料,首先与乙酰氯进行氯乙酰化反应得到1-乙酰基-4-环己基萘;得到的乙酰化中间体经过硼氢化钠还原成醇、羟基氯化和氰化钠的氰基取代,得到2-(4-环己基萘基)丙氰;该丙氰中间体通过水解得到维达洛芬。Using 1-cyclohexylnaphthalene as the starting material, firstly carry out chloroacetylation reaction with acetyl chloride to obtain 1-acetyl-4-cyclohexylnaphthalene; the obtained acetylated intermediate is reduced to alcohol, hydroxyl chloride and The cyano group of sodium cyanide is substituted to obtain 2-(4-cyclohexylnaphthyl) propanecyanide; the intermediate of propanecyanide is hydrolyzed to obtain vidaprofen.

该路线的缺点仍然是需用氰化钠等剧毒管制品,反应危险性高、操作难度大,而且还需要5步反应。The disadvantage of this route is still the need to use highly toxic control products such as sodium cyanide, high reaction risk, difficult operation, and 5-step reaction.

发明内容 Contents of the invention

针对上述问题,本发明的目的是提供一种制备化合物2-(4-环己基萘基)丙酸的新制备方法。该方法只有四步反应,步骤较短,所需原料都是常规原料,避免了剧毒品氰化钠或者氰化钾的使用。而且该路线所有步骤可以采用”一锅法”进行,且产品质量稳定,便于工业化生产。因此,该工艺易于操作,便于工业化生产。For the problems referred to above, the purpose of this invention is to provide a kind of new preparation method for preparing compound 2-(4-cyclohexylnaphthyl) propionic acid. The method has only four reaction steps, and the steps are relatively short, and the required raw materials are conventional raw materials, thereby avoiding the use of highly toxic sodium cyanide or potassium cyanide. Moreover, all steps of this route can be carried out by "one pot method", and the product quality is stable, which is convenient for industrial production. Therefore, the process is easy to operate and convenient for industrial production.

为了达到上述目的,本发明采用以下技术方案来实现。In order to achieve the above object, the present invention adopts the following technical solutions to achieve.

本发明的维达洛芬的制备方法,包括以下步骤:The preparation method of Vidaprofen of the present invention may further comprise the steps:

A)1-环己基萘(即化合物2)与2-卤代丙酰化试剂进行付-克酰化反应,得到化合物3,其反应式如下:A) 1-cyclohexylnaphthalene (i.e. compound 2) and 2-halopropionylating reagents carry out Friedel-Crafts acylation reaction to obtain compound 3, and its reaction formula is as follows:

Figure BDA0000126142220000031
Figure BDA0000126142220000031

B)化合物3用二元醇进行缩酮化保护,得到化合物4,其反应式如下:B) Compound 3 is protected by ketalization with a dihydric alcohol to obtain compound 4, the reaction formula of which is as follows:

Figure BDA0000126142220000032
Figure BDA0000126142220000032

C)化合物4在路易斯酸催化下进行芳基迁移重排,得到化合物5,其反应式如下:C) Compound 4 undergoes aryl migration rearrangement under Lewis acid catalysis to obtain compound 5, the reaction formula of which is as follows:

Figure BDA0000126142220000041
Figure BDA0000126142220000041

D)化合物5经过水解,得到维达洛芬(即化合物1),其反应式如下:D) compound 5 is hydrolyzed to obtain vidaprofen (i.e. compound 1), and its reaction formula is as follows:

Figure BDA0000126142220000042
Figure BDA0000126142220000042

其中,X为氟、氯、溴或碘,Wherein, X is fluorine, chlorine, bromine or iodine,

各R独立地为氢、甲基或乙基,each R is independently hydrogen, methyl or ethyl,

n为0、1或2;n is 0, 1 or 2;

优选地,Preferably,

X为氯或溴,X is chlorine or bromine,

各R独立地为氢或甲基,each R is independently hydrogen or methyl,

n为0或1。n is 0 or 1.

下面更详细地描述本发明的制备方法:Describe the preparation method of the present invention in more detail below:

在所述步骤A)中:In said step A):

所述2-卤代丙酰化试剂可以为2-氯丙酰氯、2-氯丙酸酐、2-溴丙酰氯或2-溴丙酸酐等;一般2-卤代丙酰化试剂与化合物2的摩尔比为1.5∶1~1∶1,并优选1.1∶1。The 2-halopropionylating reagent can be 2-chloropropionyl chloride, 2-chloropropionic anhydride, 2-bromopropionyl chloride or 2-bromopropionic anhydride, etc.; general 2-halogenating propionylating reagent and compound 2 The molar ratio is 1.5:1 to 1:1, and preferably 1.1:1.

反应使用Lewis酸作为催化剂,所述Lewis酸可为选自AlCl3、ZnCl2、BF3和TiCl4中的一种或多种,且Lewis酸与化合物2的摩尔比为2∶1~1∶1,并优选1.2∶1。其反应机理为:Lewis酸与酰氯或酸酐结合,形成的羰基正离子可以与芳环上的碳负离子结合形成碳-碳键的结构。The reaction uses a Lewis acid as a catalyst, and the Lewis acid can be one or more selected from AlCl 3 , ZnCl 2 , BF 3 and TiCl 4 , and the molar ratio of Lewis acid to compound 2 is 2:1 to 1: 1, and preferably 1.2:1. The reaction mechanism is: Lewis acid is combined with acid chloride or acid anhydride, and the carbonyl cation formed can combine with the carbanion on the aromatic ring to form a carbon-carbon bond structure.

此反应使用的溶剂可以是二氯甲烷、氯仿、1,2-二氯乙烷或氯苯等。The solvent used in this reaction can be dichloromethane, chloroform, 1,2-dichloroethane or chlorobenzene and the like.

此反应合适的温度范围为-78℃~30℃,并优选-10℃~0℃。A suitable temperature range for this reaction is -78°C to 30°C, and preferably -10°C to 0°C.

反应完成后,采用淬灭剂淬灭反应,再用有机溶剂进行提取,然后对提取得到的有机相进行减压浓缩,制得化合物3粗品,化合物3粗品无需纯化可以直接用于下一步反应。其中,所述淬灭剂可为选自水、盐酸、硫酸、甲酸、乙酸、丙酸、丁酸、草酸和柠檬酸中的一种或多种;提取所使用的有机溶剂为乙酸乙酯、甲苯、二氯甲烷或甲基叔丁基醚等。After the reaction is completed, quench the reaction with a quencher, then extract with an organic solvent, and then concentrate the extracted organic phase under reduced pressure to obtain a crude compound 3, which can be directly used in the next step without purification. Wherein, the quenching agent can be selected from one or more of water, hydrochloric acid, sulfuric acid, formic acid, acetic acid, propionic acid, butyric acid, oxalic acid and citric acid; the organic solvent used for extraction is ethyl acetate, Toluene, dichloromethane or methyl tert-butyl ether, etc.

在所述步骤B)中:In said step B):

用二元醇对化合物3上的羰基进行缩酮化保护,所述二元醇可以为乙二醇、1,3丙二醇、新戊二醇等;一般二元醇试剂与化合物3的摩尔比为3∶1~1∶1,并优选1.5∶1。Carry out ketalization protection to the carbonyl on compound 3 with dibasic alcohol, described dibasic alcohol can be ethylene glycol, 1,3 propanediol, neopentyl glycol etc.; The molar ratio of general dibasic alcohol reagent and compound 3 is 3:1 to 1:1, and preferably 1.5:1.

缩酮化反应所用的催化剂为选自硫酸、醋酸、对甲苯磺酸、甲磺酸、柠檬酸中的一种或多种;且一般酸催化剂与化合物3的摩尔比为0∶1~1∶1,并优选0.1∶1。The catalyst used in the ketalization reaction is one or more selected from sulfuric acid, acetic acid, p-toluenesulfonic acid, methanesulfonic acid, citric acid; and the molar ratio of the general acid catalyst to compound 3 is 0:1~1: 1, and preferably 0.1:1.

此反应使用的溶剂可以是苯、甲苯、二甲苯或氯苯等。反应过程中需要用分水器或其他除水装置或除水试剂将反应生成的水分及时分离除去。The solvent used in this reaction can be benzene, toluene, xylene or chlorobenzene and the like. During the reaction, it is necessary to use a water separator or other water removal devices or water removal reagents to separate and remove the water generated by the reaction in time.

该反应完成后,反应液采用水为淬灭剂来淬灭反应;有机相用水和食盐水洗涤后减压浓缩,得到化合物4粗品,化合物4的粗品无需纯化可以直接用于下一步反应。After the reaction was completed, the reaction solution was quenched with water as a quencher; the organic phase was washed with water and brine and then concentrated under reduced pressure to obtain a crude compound 4, which could be directly used in the next step without purification.

在所述步骤C)中:In said step C):

化合物4的芳基迁移重排反应使用的催化剂为选自ZnO、ZnCl2和Zn(OAc)2中的一种或多种,且催化剂与化合物4的摩尔比为0∶1~3∶1,并优选0.2∶1。其反应机理为:在锌试剂的催化下,芳基从缩酮碳上迁移至邻位的卤素原子所在碳上,同时卤素原子与锌试剂结合离去,形成化合物5的酯基结构。The catalyst used in the aryl transfer rearrangement reaction of compound 4 is one or more selected from ZnO, ZnCl 2 and Zn(OAc) 2 , and the molar ratio of catalyst to compound 4 is 0:1~3:1, And preferably 0.2:1. The reaction mechanism is: under the catalysis of the zinc reagent, the aryl group migrates from the ketal carbon to the carbon of the adjacent halogen atom, and at the same time the halogen atom combines with the zinc reagent to form the ester group structure of compound 5.

此反应使用的溶剂可以是甲苯、二甲苯或氯苯等。The solvent used in this reaction can be toluene, xylene or chlorobenzene and the like.

此反应合适的温度范围为80℃~160℃,并优选110℃~130℃。A suitable temperature range for this reaction is 80°C to 160°C, and preferably 110°C to 130°C.

该反应完成后,采用淬灭剂淬灭反应,反应有机相用水和食盐水洗涤后减压浓缩,制得化合物5粗品,化合物5粗品无需纯化可以直接用于下一步反应。其中,淬灭剂可为选自盐酸、硫酸、甲酸、乙酸和柠檬酸中的一种或多种。After the reaction was completed, the reaction was quenched with a quencher, the organic phase of the reaction was washed with water and brine, and then concentrated under reduced pressure to obtain a crude compound 5, which could be directly used in the next reaction without purification. Wherein, the quenching agent may be one or more selected from hydrochloric acid, sulfuric acid, formic acid, acetic acid and citric acid.

在所述步骤D)中:In said step D):

化合物5的水解,可以在碱性条件下,也可以在酸性条件下。水解化合物5所用的碱可以为KOH、NaOH、LiOH、K2CO3、Cs2CO3或Na2CO3等;一般碱与化合物5的摩尔比为5∶1~1∶1,并优选3∶1。水解化合物5所用的酸可以为硫酸、盐酸或对甲苯磺酸等。The hydrolysis of compound 5 can be under basic or acidic conditions. The base used for hydrolyzing compound 5 can be KOH, NaOH, LiOH, K 2 CO 3 , Cs 2 CO 3 or Na 2 CO 3 etc.; generally the molar ratio of base to compound 5 is 5:1 to 1:1, and preferably 3 : 1. The acid used for the hydrolysis of compound 5 can be sulfuric acid, hydrochloric acid or p-toluenesulfonic acid and the like.

本发明的制备方法,共计四步,合成路线短;所需原料都是常规原料,避免使用剧毒的氰化物。该路线中每步均为常规反应,后处理简单,易操作;且反应结束后,反应液经过后处理得到的粗产品无需纯化可以直接用于下一步反应,实现了整条路线“一锅法”进行,便于工业化生产。The preparation method of the present invention has a total of four steps, and the synthesis route is short; the required raw materials are all conventional raw materials, and the use of highly toxic cyanide is avoided. Each step in this route is a conventional reaction, and the post-treatment is simple and easy to operate; and after the reaction, the crude product obtained from the reaction solution after post-treatment can be directly used in the next step without purification, realizing the "one-pot method" of the whole route "Carry out, be convenient to industrialized production.

具体实施方式 Detailed ways

以下实施例进一步地说明本发明的技术方案、本发明的特征和优点,但本发明并不局限于下面的实施例。The following examples further illustrate the technical solutions, features and advantages of the present invention, but the present invention is not limited to the following examples.

1.化合物3的合成1. Synthesis of compound 3

实施例1Example 1

1-(2-氯丙酰基)-4环己基萘的合成Synthesis of 1-(2-chloropropionyl)-4cyclohexylnaphthalene

在N2保护下,于500ml三口瓶中加入AlCl3(22.8g,0.17mol)和二氯甲烷(250mL)并冷却至-10℃~0℃。搅拌下,滴加入2-氯丙酰氯(19.8g,0.157mol)和1-环己基萘(2,30.0g,0.143mol)混合物的二氯甲烷(50mL)溶液,并保持反应温度始终在-10℃~0℃。加完后,继续在-10℃~0℃保持2小时直至反应完全。将反应液倒入300mL稀盐酸(2N)中淬灭反应,搅拌分层并分离出有机层,将有机层用200mL水和200mL饱和食盐水分别洗涤后,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 , AlCl 3 (22.8 g, 0.17 mol) and dichloromethane (250 mL) were added into a 500 ml three-necked flask and cooled to -10°C to 0°C. Under stirring, a dichloromethane (50 mL) solution of a mixture of 2-chloropropionyl chloride (19.8 g, 0.157 mol) and 1-cyclohexylnaphthalene (2, 30.0 g, 0.143 mol) was added dropwise, and the reaction temperature was kept at -10 ℃~0℃. After the addition, continue to keep at -10°C to 0°C for 2 hours until the reaction is complete. The reaction solution was poured into 300mL of dilute hydrochloric acid (2N) to quench the reaction, the layers were stirred and the organic layer was separated, and the organic layer was washed with 200mL of water and 200mL of saturated brine respectively, and the solvent was evaporated under reduced pressure to obtain a crude product. Brown oily. Crude yield: Quantitative.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

MS(ESI,m/z):[M+]+301.2。MS (ESI, m/z): [M+] + 301.2.

1H-NMR(400MHz,CDCl3):δ8.52(m,1H);8.03(d,1H,J=8.8Hz);7.65~7.92(m,2H);7.42~7.60(m,2H);5.42(m,1H);2.70(m,1H);1.84-2.05(m,4H);1.80(d,3H,J=3.6Hz);1.78(m,1H);1.29-1.59(m,4H);1.31(m,1H)。 1 H-NMR (400MHz, CDCl 3 ): δ8.52(m, 1H); 8.03(d, 1H, J=8.8Hz); 7.65~7.92(m, 2H); 7.42~7.60(m, 2H); 5.42(m, 1H); 2.70(m, 1H); 1.84-2.05(m, 4H); 1.80(d, 3H, J=3.6Hz); 1.78(m, 1H); 1.29-1.59(m, 4H) ; 1.31 (m, 1H).

实施例2Example 2

在N2保护下,于500ml三口瓶中加入TiCl4(32.2g,0.17mol)和氯苯(250mL)并冷却至-10℃~0℃。搅拌下,逐滴加入2-溴丙酸酐(45.2g,0.157mol)和1-环己基萘(30.0g,0.143mol)混合物的氯苯(50mL)溶液,并保持反应温度始终在-10℃~0℃。加完后,继续在10℃~0℃保持2小时直至反应完全。将反应液倒入300mL柠檬酸水溶液(2N)中淬灭反应,搅拌分层并分离出有机层,有机层用200mL水和200mL饱和食盐水洗涤后,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 , TiCl 4 (32.2 g, 0.17 mol) and chlorobenzene (250 mL) were added into a 500 ml three-necked flask and cooled to -10°C to 0°C. Under stirring, a chlorobenzene (50mL) solution of a mixture of 2-bromopropionic anhydride (45.2g, 0.157mol) and 1-cyclohexylnaphthalene (30.0g, 0.143mol) was added dropwise, and the reaction temperature was kept at -10°C to 0°C. After the addition, continue to keep at 10°C to 0°C for 2 hours until the reaction is complete. Pour the reaction solution into 300mL citric acid aqueous solution (2N) to quench the reaction, stir and separate the layers and separate the organic layer. After the organic layer is washed with 200mL water and 200mL saturated brine, the solvent is evaporated under reduced pressure to obtain a crude product, brown Oily. Crude product yield: Quantitative.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

2.化合物4的合成2. Synthesis of compound 4

实施例3Example 3

2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环的合成Synthesis of 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane

N2气保护下,常温下于500ml三口瓶中加入1-(2-氯丙酰基)-4环己基萘(3,42.9g,0.143mol)和甲苯(430mL)。搅拌下,向反应液中加入新戊二醇(22.3g,0.214mol)和对甲苯磺酸(2.7g,0.014mol)。加毕,在反应瓶上装配分水器,然后加热至回流并保持回流20小时直至反应完全。冷却反应液至室温,加入200mL水淬灭反应,搅拌分离出有机相。有机相用水洗两次(200mL×2)、饱和食盐水(200mL)洗一次,减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 gas, 1-(2-chloropropionyl)-4cyclohexylnaphthalene (3, 42.9g, 0.143mol) and toluene (430mL) were added into a 500ml three-necked flask at room temperature. Under stirring, neopentyl glycol (22.3 g, 0.214 mol) and p-toluenesulfonic acid (2.7 g, 0.014 mol) were added to the reaction liquid. After the addition is complete, install a water separator on the reaction bottle, then heat to reflux and maintain reflux for 20 hours until the reaction is complete. Cool the reaction solution to room temperature, add 200 mL of water to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (200 mL×2) and once with saturated brine (200 mL), and the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude product yield: Quantitative.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

MS(ESI,m/z):[M+]+387.2。MS (ESI, m/z): [M+] + 387.2.

1H-NMR(400MHz,CDCl3):δ7.81~7.88(m,2H);7.38~7.51(m,3H);7.16(m,1H);4.14(m,1H);3.52(m,4H);2.70(m,1H);1.81~1.98(m,4H);1.46-1.59(m,4H);1.25~1.44(m,7H)。 1 H-NMR (400MHz, CDCl 3 ): δ7.81~7.88(m, 2H); 7.38~7.51(m, 3H); 7.16(m, 1H); 4.14(m, 1H); 3.52(m, 4H ); 2.70 (m, 1H); 1.81-1.98 (m, 4H); 1.46-1.59 (m, 4H); 1.25-1.44 (m, 7H).

实施例4Example 4

N2气保护下,常温下于500ml三口瓶中加入1-(2-氯丙酰基)-4环己基萘(3,42.9g,0.143mol)和二甲苯(430mL)。搅拌下,向反应液中加入乙二醇(13.3g,0.214mol)和浓硫酸(1.4g,0.014mol)。加毕,在反应瓶上装配分水器,然后加热至回流并保持回流20小时直至反应完全。冷却反应液至室温,加入200mL水淬灭反应,搅拌分离出有机相。有机相用水洗两次(200mL×2)、饱和食盐水(200mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:定量。Under the protection of N 2 gas, 1-(2-chloropropionyl)-4cyclohexylnaphthalene (3, 42.9g, 0.143mol) and xylene (430mL) were added into a 500ml three-necked flask at room temperature. Under stirring, ethylene glycol (13.3 g, 0.214 mol) and concentrated sulfuric acid (1.4 g, 0.014 mol) were added to the reaction liquid. After the addition is complete, install a water separator on the reaction bottle, then heat to reflux and maintain reflux for 20 hours until the reaction is complete. Cool the reaction solution to room temperature, add 200 mL of water to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (200 mL×2) and once with saturated brine (200 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: Quantitative.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

MS(ESI,m/z):[M+]+345.1。MS (ESI, m/z): [M+] + 345.1.

3.化合物5的合成3. Synthesis of Compound 5

实施例5Example 5

3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯的合成Synthesis of 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate

在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(4,55.2g,0.143mol)、氧化锌(2.4g,0.029mol)和甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌16小时以上直至反应完全。冷却反应液至室温,加入100mL稀硫酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:90%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 4, 55.2 g, 0.143 mol), zinc oxide (2.4 g, 0.029 mol) and toluene (200 mL). The reaction solution was heated to 110°C-130°C and kept at this temperature and stirred for more than 16 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute sulfuric acid (2N) to quench the reaction, stir and separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 90%.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

MS(ESI,m/z):[M+]+387.2。MS (ESI, m/z): [M+] + 387.2.

1H-NMR(400MHz,CDCl3):δ7.60~7.80(m,4H);7.40(m,2H);3.89(m,3H);3.12(m,2H);2.65(m,1H);1.90-1.98(m,4H);1.87(m,1H);1.77(d,3H,J=7.2Hz);1.25-1.51(m,4H);1.26(m,1H);0.81(m,6H)。 1 H-NMR (400MHz, CDCl 3 ): δ7.60~7.80(m, 4H); 7.40(m, 2H); 3.89(m, 3H); 3.12(m, 2H); 2.65(m, 1H); 1.90-1.98(m, 4H); 1.87(m, 1H); 1.77(d, 3H, J=7.2Hz); 1.25-1.51(m, 4H); 1.26(m, 1H); 0.81(m, 6H) .

实施例6Example 6

在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(55.2g,0.143mol)、氧化锌(2.4g,0.029mol)、氯化锌(3.9g,0.029mol)和二甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌4小时以上直至反应完全。冷却反应液至室温,加入100mL稀盐酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:90%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 55.2 g, 0.143 mol), zinc oxide (2.4 g, 0.029 mol), zinc chloride (3.9 g, 0.029 mol) and xylene (200 mL). The reaction liquid was heated to 110° C. to 130° C. and kept at this temperature and stirred for more than 4 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute hydrochloric acid (2N) to quench the reaction, and stir to separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 90%.

粗品无需纯化可以直接用于下一步反应。The crude product was directly used in the next reaction without further purification.

实施例7Example 7

在N2保护下,向500mL反应瓶中加入2-(1-氯乙基)-2-(4-环己基萘基)-5,5-二甲基-1,3-二氧六环(55.2g,0.143mol)、醋酸锌(5.4g,0.029mol)和二甲苯(200mL)。将反应液加热至110℃~130℃并保持在该温度搅拌6小时以上直至反应完全。冷却反应液至室温,加入100mL稀盐酸(2N)淬灭反应,搅拌分离出有机相。有机相用水洗两次(150mL×2)、饱和食盐水(150mL)洗一次,然后减压蒸除溶剂,得粗产品,棕色油状。粗品收率:85%。Under N protection, 2-(1-chloroethyl)-2-(4-cyclohexylnaphthyl)-5,5-dimethyl-1,3-dioxane ( 55.2 g, 0.143 mol), zinc acetate (5.4 g, 0.029 mol) and xylene (200 mL). The reaction solution was heated to 110° C. to 130° C. and kept at this temperature and stirred for more than 6 hours until the reaction was complete. Cool the reaction solution to room temperature, add 100 mL of dilute hydrochloric acid (2N) to quench the reaction, and stir to separate the organic phase. The organic phase was washed twice with water (150 mL×2) and once with saturated brine (150 mL), and then the solvent was evaporated under reduced pressure to obtain a crude product as a brown oil. Crude yield: 85%.

4.化合物1【维达洛芬】的合成4. Synthesis of Compound 1 [Vidaprofen]

实施例8Example 8

室温下向500mL三口反应瓶中,加入3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯(5,50.0g,0.13mol)、四氢呋喃(150mL)和甲醇(150mL);搅拌5分钟至固体溶清后,向反应液中加入52mL氢氧化钠水溶液(23%)。得到的反应混合物加热至60℃~70℃反应2小时,直至反应完全。将反应液冷却至室温,减压蒸除有机溶剂,得到的棕色悬浊液用100mL水稀释,然后加入200mL乙酸乙酯萃取。分出有机层,有机相在室温下搅拌1小时,再冷却至0℃~10℃搅拌1小时。过滤,滤饼用乙酸乙酯洗涤(40mL×2)得到白色固体为维达洛芬的钠盐。将得到的白色固体投入100mL稀盐酸(2N)中,搅拌30分钟后过滤,滤饼用水洗两次(40mL×2)得到白色固体,该固体在50℃真空条件下干燥大约16小时得到白色固体,即维达洛芬。收率:~30%,纯度99.7%。To a 500mL three-neck reaction flask at room temperature, add 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate (5, 50.0g, 0.13mol), tetrahydrofuran (150mL) and methanol (150 mL); after stirring for 5 minutes until the solid dissolved, 52 mL of aqueous sodium hydroxide solution (23%) was added to the reaction solution. The obtained reaction mixture was heated to 60° C. to 70° C. for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, and the organic solvent was distilled off under reduced pressure. The resulting brown suspension was diluted with 100 mL of water, and then extracted with 200 mL of ethyl acetate. The organic layer was separated, and the organic phase was stirred at room temperature for 1 hour, then cooled to 0°C-10°C and stirred for 1 hour. After filtering, the filter cake was washed with ethyl acetate (40 mL×2) to obtain a white solid which was the sodium salt of vidaprofen. The obtained white solid was put into 100 mL of dilute hydrochloric acid (2N), stirred for 30 minutes, filtered, and the filter cake was washed twice with water (40 mL×2) to obtain a white solid, which was dried at 50°C under vacuum for about 16 hours to obtain a white solid , vidaprofen. Yield: ~30%, purity 99.7%.

MS(ESI,m/z):[M+]+283.4。MS (ESI, m/z): [M+] + 283.4.

1H-NMR(400MHz,DMSO-d6):δ7.73(d,2H,J=8.0Hz);7.65(d,2H,J=17.6Hz);6.84(dd,2H,J1=8.0Hz,J2=18.8Hz);3.69(m,1H);2.64(m,1H);1.80-1.90(m,4H);1.73(m,1H);1.35-1.55(m,4H);1.38(d,3H,J=7.2Hz);1.27(m,1H)。 1 H-NMR (400MHz, DMSO-d 6 ): δ7.73 (d, 2H, J = 8.0Hz); 7.65 (d, 2H, J = 17.6Hz); 6.84 (dd, 2H, J 1 = 8.0Hz , J 2 =18.8Hz); 3.69(m, 1H); 2.64(m, 1H); 1.80-1.90(m, 4H); 1.73(m, 1H); 1.35-1.55(m, 4H); , 3H, J=7.2Hz); 1.27(m, 1H).

实施例9Example 9

室温下向500mL三口反应瓶中,加入3-氯-2,2-二甲基丙基2-(4-环己基萘基)丙酸酯(50.0g,0.13mol)、丙酮(300mL);搅拌5分钟至固体溶清后,向反应液中加入150mL碳酸钾水溶液(30%)。得到的反应混合物加热至60℃~70℃反应2小时,直至反应完全。将反应液冷却至室温,减压蒸除有机溶剂,得到的棕色悬浊液用100mL水稀释,然后加入200mL甲基叔丁基醚萃取。分出有机层,有机相在室温下搅拌1小时,再冷却至0℃~10℃搅拌1小时。过滤,滤饼用甲基叔丁基醚洗涤(40mL×2)得到白色固体为维达洛芬的钠盐。将得到的白色固体投入100mL稀盐酸(2N)中,搅拌30分钟后过滤,滤饼用水洗两次(40mL×2)得到白色固体,该固体在50℃真空条件下干燥大约16小时得到白色固体,即维达洛芬。收率:~30%,纯度99.7%。Add 3-chloro-2,2-dimethylpropyl 2-(4-cyclohexylnaphthyl)propionate (50.0g, 0.13mol) and acetone (300mL) to a 500mL three-necked reaction flask at room temperature; stir After 5 minutes until the solid dissolved, 150 mL of potassium carbonate aqueous solution (30%) was added to the reaction liquid. The obtained reaction mixture was heated to 60° C. to 70° C. for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, and the organic solvent was distilled off under reduced pressure. The obtained brown suspension was diluted with 100 mL of water, and then extracted by adding 200 mL of methyl tert-butyl ether. The organic layer was separated, and the organic phase was stirred at room temperature for 1 hour, then cooled to 0°C-10°C and stirred for 1 hour. After filtering, the filter cake was washed with methyl tert-butyl ether (40 mL×2) to obtain a white solid which was the sodium salt of vidaprofen. The obtained white solid was put into 100 mL of dilute hydrochloric acid (2N), stirred for 30 minutes, filtered, and the filter cake was washed twice with water (40 mL×2) to obtain a white solid, which was dried at 50°C under vacuum for about 16 hours to obtain a white solid , vidaprofen. Yield: ~30%, purity 99.7%.

以上描述和说明了本发明的基本原理、主要特征和优点。本领域的技术人员应该理解,本发明不受上述实施例的限制,上述实施例和说明书中描述的实施方案只是用于说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书界定。The foregoing describes and illustrates the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited by the above examples, and that the above examples and implementations described in the specification are only used to illustrate the principle of the present invention, and without departing from the spirit and scope of the present invention, the present invention The invention also has various changes and improvements, and these changes and improvements all fall within the scope of the claimed invention. The protection scope of the present invention is defined by the appended claims.

Claims (8)

1.一种合成维达洛芬的方法,包括以下步骤:1. A method for synthesizing Vidaprofen, comprising the following steps: A)化合物2与2-卤代丙酰化试剂进行付-克酰化反应,得到化合物3,其反应式如下:A) The Friedel-Crafts acylation reaction of compound 2 with a 2-halopropionylating reagent yields compound 3, whose reaction formula is as follows: B)化合物3用二元醇进行缩酮化保护,得到化合物4,其反应式如下:B) Compound 3 is protected by ketalization with a dihydric alcohol to obtain compound 4, the reaction formula of which is as follows:
Figure FDA0000126142210000012
Figure FDA0000126142210000012
C)化合物4在路易斯酸催化下进行芳基迁移重排,得到化合物5,其反应式如下:C) Compound 4 undergoes aryl migration rearrangement under Lewis acid catalysis to obtain compound 5, the reaction formula of which is as follows:
Figure FDA0000126142210000013
Figure FDA0000126142210000013
D)化合物5经过水解,得到维达洛芬1,其反应式如下:D) compound 5 is hydrolyzed to obtain vidaprofen 1, and its reaction formula is as follows:
Figure FDA0000126142210000014
Figure FDA0000126142210000014
其中,X为氟、氯、溴或碘,Wherein, X is fluorine, chlorine, bromine or iodine, 各R独立地为氢、甲基或乙基,each R is independently hydrogen, methyl or ethyl, n为0、1或2。n is 0, 1 or 2.
2.根据权利要求1所述的方法,其中,在所述步骤A)中,所述2-卤代丙酰化试剂为2-氯丙酰氯、2-氯丙酸酐、2-溴丙酰氯或2-溴丙酸酐;所述2-卤代丙酰化试剂与化合物2的摩尔比为1.5∶1~1∶1。2. The method according to claim 1, wherein, in the step A), the 2-halopropionylating reagent is 2-chloropropionyl chloride, 2-chloropropionic anhydride, 2-bromopropionyl chloride or 2-bromopropionic anhydride; the molar ratio of the 2-halopropionylating reagent to compound 2 is 1.5:1˜1:1. 3.根据权利要求1所述的方法,其中,在所述步骤A)中,使用Lewis酸作为催化剂,所述Lewis酸为选自AlCl3、ZnCl2、BF3、TiCl4中的一种或多种。3. The method according to claim 1, wherein, in the step A), a Lewis acid is used as a catalyst, and the Lewis acid is selected from AlCl 3 , ZnCl 2 , BF 3 , TiCl 4 or Various. 4.根据权利要求1所述的方法,其中,在所述步骤A)中,反应使用的溶剂为二氯甲烷、氯仿、二氯乙烷或氯苯;反应温度范围为-78℃~30℃。4. The method according to claim 1, wherein, in the step A), the solvent used in the reaction is methylene chloride, chloroform, ethylene dichloride or chlorobenzene; the reaction temperature range is -78°C to 30°C . 5.根据权利要求1所述的方法,其中,在所述步骤B)中,所述二元醇为乙二醇、1,3丙二醇或新戊二醇;所述二元醇与化合物3的摩尔比为3∶1~1∶1。5. method according to claim 1, wherein, in described step B) in, described dibasic alcohol is ethylene glycol, 1,3 propylene glycol or neopentyl glycol; Described dibasic alcohol and compound 3 The molar ratio is 3:1 to 1:1. 6.根据权利要求1所述的方法,其中,在所述步骤B)中,所述缩酮化反应使用的催化剂为选自硫酸、醋酸、对甲苯磺酸、甲磺酸、柠檬酸中的一种或多种;所述催化剂与化合物3的摩尔比为0∶1~1∶1。6. The method according to claim 1, wherein, in the step B), the catalyst used in the ketalization reaction is selected from sulfuric acid, acetic acid, p-toluenesulfonic acid, methanesulfonic acid, citric acid One or more; the molar ratio of the catalyst to the compound 3 is 0:1˜1:1. 7.根据权利要求1所述的方法,其中,在所述步骤C)中,重排反应采用的催化剂为选自ZnO、ZnCl2和Zn(OAc)2中的一种或多种,且所述催化剂与化合物4的摩尔比为0∶1~3∶1。7. method according to claim 1, wherein, in described step C) in, the catalyst that rearrangement reaction adopts is selected from ZnO, ZnCl 2 and Zn(OAc) 2 in one or more, and the The molar ratio of the catalyst to the compound 4 is 0:1-3:1. 8.根据权利要求1所述的方法,其中,在所述步骤C)中,使用的溶剂为甲苯、二甲苯或氯苯;反应温度范围为80℃~160℃。8. The method according to claim 1, wherein, in the step C), the solvent used is toluene, xylene or chlorobenzene; the reaction temperature ranges from 80°C to 160°C.
CN201110448572.2A 2011-12-28 2011-12-28 The preparation method of Vedaprofen Active CN103183604B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110448572.2A CN103183604B (en) 2011-12-28 2011-12-28 The preparation method of Vedaprofen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110448572.2A CN103183604B (en) 2011-12-28 2011-12-28 The preparation method of Vedaprofen

Publications (2)

Publication Number Publication Date
CN103183604A true CN103183604A (en) 2013-07-03
CN103183604B CN103183604B (en) 2015-07-29

Family

ID=48675084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110448572.2A Active CN103183604B (en) 2011-12-28 2011-12-28 The preparation method of Vedaprofen

Country Status (1)

Country Link
CN (1) CN103183604B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710309A (en) * 2015-02-05 2015-06-17 浙江普洛医药科技有限公司 Synthetic methods of loxoprofen sodium and intermediate thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218473A (en) * 1977-10-03 1980-08-19 Centre Europeen De Recherches Mauvernay Derivatives of 4-cyclohexyl-1-naphthalene-acetic acid and their use as drugs
US4623736A (en) * 1982-07-09 1986-11-18 The Upjohn Company Arylalkanoic acid process improvement
CN1082022A (en) * 1992-08-14 1994-02-16 山东新华制药厂 Molecular transposition prepares the technology of Ibuprofen BP/EP under the catalysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218473A (en) * 1977-10-03 1980-08-19 Centre Europeen De Recherches Mauvernay Derivatives of 4-cyclohexyl-1-naphthalene-acetic acid and their use as drugs
US4623736A (en) * 1982-07-09 1986-11-18 The Upjohn Company Arylalkanoic acid process improvement
CN1082022A (en) * 1992-08-14 1994-02-16 山东新华制药厂 Molecular transposition prepares the technology of Ibuprofen BP/EP under the catalysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORESTE PICCOLO等: "Zinc Salt Catalyzed Rearrangement of Acetals of Optically Active Aryl 1-Chloroethyl Ketones: Synthesis of Optically Active 2-Arylpropionic Acids and Esters", 《J.ORG.CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710309A (en) * 2015-02-05 2015-06-17 浙江普洛医药科技有限公司 Synthetic methods of loxoprofen sodium and intermediate thereof

Also Published As

Publication number Publication date
CN103183604B (en) 2015-07-29

Similar Documents

Publication Publication Date Title
US7323587B2 (en) Selective estrogen receptor modulators
US11465970B2 (en) Method for synthesis of Roxadustat and intermediate compounds thereof
JP5208239B2 (en) Novel production method of anticancer active tricyclic compounds by alkyne coupling
CN102627573B (en) Synthesis method for 5-aminolevulinic acid hydrochloride
CN103755541B (en) One class chalcone derivative and its production and use
CN113603568A (en) Preparation method of cannabidiol
CN108623456A (en) The preparation method of butylphenyl phthaleine and its pharmaceutical intermediate
CN111423394B (en) Synthesis method of 1,3, 4-oxadiazole heterocyclic compound
CN102070586A (en) Process method for synthesizing 4-site heteroatom-substituted cyclohexenyl halide
CN103613568B (en) The preparation method of a kind of Naphtonone and analogue thereof
CN110256451A (en) A kind of synthetic method of benzofuran simultaneously [2,3-b] quinoline
CN101200442A (en) Process for preparing [1-(mercaptomethyl)cyclopropyl]acetic acid and derivatives thereof
CN102267934B (en) Method for preparing 6-carbomethoxy indolone
CN103183604A (en) Preparation method of vedaprofen
CN114736183A (en) Preparation method of 3-methylflavone-8-carboxylic acid
WO2017152539A1 (en) 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound
CN113214199B (en) A kind of synthetic method of benzofuran-3-oxocarboxylate compound
CN103420962B (en) 3-aryl glutaric acid monoester class compound, Preparation Method And The Use
JP6256469B2 (en) Process for the preparation of spiro [2.5] octane-5,7-dione
JP5918624B2 (en) Optically active fluorine-containing 5,6-dihydropyridone derivative and process for producing the same
CN101830872A (en) Synthetic method of 3-hydroxyl benzofuran derivatives
CN101397247A (en) Method for synthesizing raw medicine dihydroindene-1-carboxyl acid for clidabac
CN101486643A (en) Trans naproxen ester, optical isomer thereof, as well as preparation and use thereof
CN101456843A (en) Synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid
HU195659B (en) Process for producing cotarnine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant